TargetMol

ARV-471

Product Code:
 
TAR-T39710
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T39710-1mg1mg£283.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T39710-5mg5mg£598.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T39710-1mL1 mL * 10 mM (in DMSO)£790.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T39710-10mg10mg£821.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T39710-25mg25mg£1,187.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T39710-50mg50mg£1,589.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
ARV-471 is a orally active Cereblon -based estrogen receptor ( ER ) PROTAC degrader. ARV-471 is developed for the research of breast cancer.
CAS:
2229711-68-4
Formula:
C45H49N5O4
Molecular Weight:
723.9
Pathway:
Endocrinology/Hormones
Purity:
0.9715
SMILES:
Oc1cc(CC[C@@H]([C@@H]2c(cc3)ccc3N3CCC(CN(CC4)CCN4c(cc4)cc(CN5[C@@H](CCC(N6)=O)C6=O)c4C5=O)CC3)c3ccccc3)c2cc1
Target:
Estrogen Receptor/ERR

References

John J. Flanagan, et al. ARV-471, an oral estrogen receptor PROTAC? protein degrader for breast cancer. American Association for Cancer Research.2019. 79 (4): P5-04-18.